- Home
- OUT vs MLYS Comparison
OUT vs MLYS Comparison
Compare OUT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUT
- MLYS
- Stock Information
- Founded
- OUT 2013
- MLYS 2019
- Country
- OUT United States
- MLYS United States
- Employees
- OUT N/A
- MLYS N/A
- Industry
- OUT Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- OUT Real Estate
- MLYS Health Care
- Exchange
- OUT Nasdaq
- MLYS Nasdaq
- Market Cap
- OUT 3.2B
- MLYS 3.1B
- IPO Year
- OUT N/A
- MLYS 2023
- Fundamental
- Price
- OUT $17.22
- MLYS $41.76
- Analyst Decision
- OUT Buy
- MLYS Strong Buy
- Analyst Count
- OUT 7
- MLYS 6
- Target Price
- OUT $19.44
- MLYS $42.60
- AVG Volume (30 Days)
- OUT 1.2M
- MLYS 1.5M
- Earning Date
- OUT 11-06-2025
- MLYS 11-10-2025
- Dividend Yield
- OUT 6.88%
- MLYS N/A
- EPS Growth
- OUT N/A
- MLYS N/A
- EPS
- OUT 0.60
- MLYS N/A
- Revenue
- OUT $1,796,000,000.00
- MLYS N/A
- Revenue This Year
- OUT N/A
- MLYS N/A
- Revenue Next Year
- OUT $2.79
- MLYS N/A
- P/E Ratio
- OUT $29.04
- MLYS N/A
- Revenue Growth
- OUT N/A
- MLYS N/A
- 52 Week Low
- OUT $12.95
- MLYS $8.24
- 52 Week High
- OUT $19.98
- MLYS $43.88
- Technical
- Relative Strength Index (RSI)
- OUT 37.19
- MLYS 68.16
- Support Level
- OUT $17.04
- MLYS $37.54
- Resistance Level
- OUT $17.68
- MLYS $43.88
- Average True Range (ATR)
- OUT 0.43
- MLYS 2.20
- MACD
- OUT -0.12
- MLYS -0.45
- Stochastic Oscillator
- OUT 11.90
- MLYS 75.25
About OUT OUTFRONT Media Inc.
Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The Company generates revenue in the form of rental income by allowing other companies to advertise on its properties and structures under short-term contracts. Outfront Media segments its operations into the United States and International units. Although it also owns assets in Canada and Latin America, the company derives the vast majority of its revenue from billboard advertising agreements in the U.S. Roughly half of the U.S. division's revenue comes from its displays in the New York City and Los Angeles markets. Outfront Media's customers include entities within the retail, television, healthcare, and entertainment industries.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.